Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Pilot Study of Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study

NCT04836390 is registered in ClinicalTrials.gov with Michael Pulsipher as lead sponsor.

NCT NCT04836390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04836390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Pilot Study of Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study
Lead sponsor
Michael Pulsipher
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
August 24, 2021
Completion date
May 31, 2028
Enrollment
30 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia